Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by wrongturnon Nov 07, 2007 1:57am
266 Views
Post# 13765325

MD&A - Positive Angle

MD&A - Positive AngleI read the Strategic Outlook again. Another view - they will use the data from phase III trials in discussions with Roche transplantation. Which makes sense, why wouldn't they discuss the data. However, if Roche decides not to opt in for transplantation, the company (ISA) will not go at the next phase III trials for psoriasis alone. At this point the company will seek partnerships for possibly both indications. I cannot see ISA partnering with Roche for psoriasis. The only way Roche will significantly affect psoriasis trials is if Roche does not opt in for transplantation. For the longs, hang onto your shares, we're going to make it. Again, just looking at things from a positive angle this time. May be I'm just getting desperate.
Bullboard Posts